Publications by authors named "Joaquin M Lopez"
Article Synopsis
- Doctors are unsure about the best time to start treatment for patients with relapsed/refractory multiple myeloma (RRMM) after they start getting worse again.
- A study looked at two groups, one that started treatment early (when the disease started to show signs) and the other that waited until symptoms got worse.
- The group that waited showed better treatment results, lasting longer without the disease getting worse compared to the group that started treatment early.
The role of high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) in the treatment of myeloma (MM) patients with severe and/or dialysis-dependent renal impairment remains uncertain. We report on the outcomes of 110 patients (median age 57 years) who had become dialysis-dependent pre-ASCT and who underwent a first ASCT between 1997 and 2017. Sixty-three (57%) patients had light chain MM.
View Article and Find Full Text PDFMonoclonal gammopathies of clinical significance (MGCSs) represent a group of diseases featuring the association of a nonmalignant B cells or plasma cells clone, the production of an M-protein, and singularly, the existence of organ damage. They present a current framework that is difficult to approach from a practical clinical perspective. Several points should be addressed in order to move further toward a better understanding.
View Article and Find Full Text PDFArticle Synopsis
- * Researchers conducted a multi-center case-control study with 480 MPN patients and 909 healthy controls, discovering that individuals in the highest quintile of the "teloscore" had nearly double the risk of developing MPNs compared to those in the lowest quintile.
- * Specific genetic variants, particularly TERT-rs2736100-C and OBFC1-rs9420907-C, were confirmed as associated with both longer telomeres
Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis.
Haematologica
December 2019
Background: Induction schedules in acute myeloid leukemia (AML) are based on combinations of cytarabine and anthracyclines. The choice of the anthracycline employed has been widely studied in multiple clinical trials showing similar complete remission rates.
Materials And Methods: Using an test we have analyzed if a subset of AML patients may respond differently to cytarabine combined with idarubicin, daunorubicin or mitoxantrone.
Purpose: To study the prognostic significance of the presence of breast cancer-specific mRNA transcripts in peripheral blood (PB), defined by serial analysis of gene expression, in high-risk breast cancer (HRBC) patients undergoing high-dose chemotherapy after receiving adjuvant chemotherapy.
Methods: From 1994 to 2000, 84 HRBC patients (median age, 44 years; > 10 nodes; 74%) received adjuvant chemotherapy (fluorouracil, epirubicin, and cyclophosphamide for six cycles [83%] or doxorubicin and cyclophosphamide followed by paclitaxel) before undergoing one course of cyclophosphamide plus thiotepa plus carboplatin (STAMP V). Radiotherapy or hormone therapy was administered whenever indicated.